EyeGate Pharmaceuticals Inc. (EYEG) had the misfortune of entering into a worldwide licensing agreement with Valeant Pharmaceuticals International Inc. (VRX) in July 2015, just before scandal rocked the blue chip drug manufacturer. It hit an all-time high at $35 after the news and then plummeted, dropping back into single digits in August. The stock posted lower lows into November 2016 and gapped up on heavy volume on Feb. 21 after renewing that agreement. It should fare better this time around, heading toward an upside target between $5.00 and $8.00.
